Search results
Showing 781 to 795 of 1834 results for carers
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]
In development Reference number: GID-TA11116 Expected publication date: 29 July 2026
Awaiting development Reference number: GID-TA10972 Expected publication date: TBC
Awaiting development Reference number: GID-TA11670 Expected publication date: TBC
In development Reference number: GID-TA11308 Expected publication date: TBC
In development Reference number: GID-TA11094 Expected publication date: TBC
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]
Awaiting development Reference number: GID-TA10971 Expected publication date: TBC
The guidance development timeline
This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.
In development Reference number: GID-TA11760 Expected publication date: TBC
In development Reference number: GID-TA11823 Expected publication date: TBC
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]
Awaiting development Reference number: GID-TA11087 Expected publication date: TBC
Awaiting development Reference number: GID-TA11639 Expected publication date: TBC
Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]
Awaiting development Reference number: GID-TA11855 Expected publication date: TBC
Awaiting development Reference number: GID-TA11624 Expected publication date: TBC
This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.